New nanoparticle technology offers hope for hard-to-treat diseases [Yahoo! Finance]
Arvinas, Inc. (ARVN)
Last arvinas, inc. earnings: 11/4 05:00 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
research led by University of Technology Chair Professor in Nanomedicine Bingyang Shi. A newly published perspective article in Nature Nanotechnology details groundbreaking nanoparticle technology to eliminate harmful, disease-causing proteins in the body. The technology marks a transformative leap in the potential to drug “undruggable” proteins, to treat diseases such as dementia and brain cancer. The research was led by Chair Professor in Nanomedicine Bingyang Shi from the University of Technology Sydney (UTS), together with international collaborators Professor Kam Leong from Columbia University, and Professor Meng Zheng from Henan University. “Proteins are essential for nearly every function in the body, but when they become mutated, misfolded, overproduced, or build up in the wrong place, they can disrupt normal cell processes and trigger disease,” said Professor Shi. “Many conditions, including cancer, dementia and autoimmune disorders, are driven by abnormal proteins, a
Show less
Read more
Impact Snapshot
Event Time:
ARVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARVN alerts
High impacting Arvinas, Inc. news events
Weekly update
A roundup of the hottest topics
ARVN
News
- Here's Why We're Not Too Worried About Arvinas' (NASDAQ:ARVN) Cash Burn Situation [Yahoo! Finance]Yahoo! Finance
- Arvinas (NASDAQ:ARVN) was upgraded by analysts at Citigroup Inc. from a "neutral" rating to a "buy" rating.MarketBeat
- Arvinas (NASDAQ:ARVN) was given a new $18.00 price target on by analysts at Barclays PLC. They now have an "overweight" rating on the stock.MarketBeat
- How the Narrative Surrounding Pfizer Is Changing After Obesity Deals and Sector Rerating [Yahoo! Finance]Yahoo! Finance
- Arvinas (NASDAQ:ARVN) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
ARVN
Earnings
- 11/5/25 - Beat
ARVN
Sec Filings
- 12/8/25 - Form 8-K
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- ARVN's page on the SEC website